M05.059 Felty's syndrome, unspecified hip

Name of the Condition

• Felty's syndrome, unspecified hip

Summary

Felty's syndrome is a rare complication of rheumatoid arthritis characterized by the triad of rheumatoid arthritis, splenomegaly (enlarged spleen), and neutropenia (low neutrophil count). When affecting the hip, it involves chronic inflammation of the hip joint alongside systemic manifestations. The condition typically occurs in individuals with long-standing, severe rheumatoid arthritis and is associated with increased susceptibility to infections due to neutropenia.

Causes

Felty's syndrome is considered a variant of rheumatoid arthritis, though its exact cause is not fully understood. It is thought to result from chronic inflammation and immune dysregulation, leading to splenic sequestration of neutrophils and bone marrow suppression. The condition is strongly associated with high titers of rheumatoid factor and anti-citrullinated protein antibodies (ACPA). Hip involvement occurs as part of the broader rheumatoid arthritis process affecting multiple joints.

Risk Factors

• Long-standing, severe rheumatoid arthritis
• High titers of rheumatoid factor
• Presence of anti-citrullinated protein antibodies (ACPA)
• Advanced age (typically over 50 years)
• Female gender (more commonly affected)

Symptoms

• Persistent joint pain, swelling, and stiffness in the hip from underlying rheumatoid arthritis
• Fatigue and weakness
• Recurrent infections due to neutropenia
• Abdominal discomfort or fullness from splenomegaly
• Unexplained weight loss
• Skin discoloration or ulcers (less common)

Diagnosis

Diagnosis of Felty's syndrome, unspecified hip, requires confirmation of the triad of rheumatoid arthritis, splenomegaly, and neutropenia, along with hip joint involvement. Clinical evaluation includes assessing joint symptoms, splenic size, and blood counts. Laboratory tests may include complete blood counts, rheumatoid factor, and anti-citrullinated protein antibodies. Imaging studies, such as X-rays or MRI of the hip, can evaluate joint damage. Bone marrow biopsy may be considered if bone marrow suppression is suspected.

Treatment Options

Treatment focuses on managing rheumatoid arthritis and its complications. Disease-modifying antirheumatic drugs (DMARDs) are used to control inflammation. Granulocyte colony-stimulating factor (G-CSF) may address neutropenia. Splenectomy is rarely performed. Hip-specific treatments include physical therapy, pain management, and, in severe cases, joint replacement surgery. Infections require prompt antibiotic therapy.

Prognosis and Follow-Up

Prognosis depends on the severity of rheumatoid arthritis and response to treatment. Neutropenia increases infection risk, which can impact outcomes. Regular monitoring of blood counts, joint function, and infection signs is essential. Follow-up care involves rheumatologists and orthopedic specialists to manage both systemic and hip-related symptoms.

Complications

• Increased susceptibility to infections due to neutropenia
• Severe joint damage in the hip, potentially leading to disability
• Splenic rupture (rare)
• Anemia or other blood cell deficiencies
• Increased risk of lymphoma in long-standing cases

Lifestyle & Prevention

• Maintain regular follow-up with healthcare providers to monitor disease activity.
• Practice good hygiene to reduce infection risk.
• Engage in gentle exercise to preserve hip mobility and strength.
• Avoid smoking, which worsens rheumatoid arthritis.
• Ensure vaccinations are up to date, as advised by a healthcare provider.

When to Seek Professional Help

Seek medical attention if you experience:

• Worsening hip pain, swelling, or stiffness.
• Signs of infection, such as fever, chills, or persistent sore throat.
• Unexplained fatigue, weight loss, or abdominal fullness.
• New or worsening skin changes, such as ulcers.

Tips for Medical Coders

Use M05.059 for Felty's syndrome with unspecified hip involvement. Document the presence of rheumatoid arthritis, splenomegaly, and neutropenia to support the diagnosis. Specify hip involvement as "unspecified" only when the side (right or left) is not documented. Ensure clinical correlation with the triad of symptoms and any hip-specific findings.